Search research articles
Contact Us
Filters
Showing results (1-10 of 157) with videos related to
Page
of 16
Sort By:
The Lancet. Oncology
|
November 17, 2024
Retrospective analysis of immunotherapy outcomes in Black patients
Kerry L Reynolds, Pauline Funchain
The Oncologist
|
November 29, 2018
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature
Kerry L Reynolds, Amanda C Guidon
Menopause (New York, N.Y.)
|
June 14, 2013
Endocrine therapy for breast cancer: a tough pill to swallow
Kerry L Reynolds, Michaela J Higgins
The Oncologist
|
March 24, 2019
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review
Meghan E Sise, Harish Seethapathy, Kerry L Reynolds
JCO Oncology Practice
|
April 21, 2025
Beyond the Point: Learning From Outcomes After Inpatient Immune Checkpoint Inhibitor Therapy
Ali Raza Khaki, Kerry L Reynolds, Laura A Petrillo
JCO Oncology Practice
|
December 19, 2024
It Takes a Village! Navigating the Challenges and Opportunities in Immune-Related Adverse Event Management
Maysa Vilbert, Leyre Zubiri, Meghan J Mooradian, et al.
Neuro-Oncology Advances
|
December 3, 2021
A review of neurotoxicities associated with immunotherapy and a framework for evaluation
Leeann B Burton, Mahsa Eskian, Amanda C Guidon, et al.
JAMA Network Open
|
October 14, 2020
Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
Tina R Watson, Xin Gao, Kerry L Reynolds, et al.
Current Cardiology Reports
|
July 1, 2021
Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors
David J Lee, Howard J Lee, Jocelyn R Farmer, et al.
Best Practice & Research. Clinical Haematology
|
September 7, 2025
Corrigendum to "Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)" [Best Pract Res Clin Haematol 38 2 2025]
Matthew J Hadfield, Ross D Merkin, Sherin J Rouhani, et al.
Page
of 16
Search research articles
Search
Showing results (1-10 of 157) with videos related to
Sort By:
Page
of 16
The Lancet. Oncology
|
November 17, 2024
Retrospective analysis of immunotherapy outcomes in Black patients
Kerry L Reynolds, Pauline Funchain
The Oncologist
|
November 29, 2018
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature
Kerry L Reynolds, Amanda C Guidon
Menopause (New York, N.Y.)
|
June 14, 2013
Endocrine therapy for breast cancer: a tough pill to swallow
Kerry L Reynolds, Michaela J Higgins
The Oncologist
|
March 24, 2019
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review
Meghan E Sise, Harish Seethapathy, Kerry L Reynolds
JCO Oncology Practice
|
April 21, 2025
Beyond the Point: Learning From Outcomes After Inpatient Immune Checkpoint Inhibitor Therapy
Ali Raza Khaki, Kerry L Reynolds, Laura A Petrillo
JCO Oncology Practice
|
December 19, 2024
It Takes a Village! Navigating the Challenges and Opportunities in Immune-Related Adverse Event Management
Maysa Vilbert, Leyre Zubiri, Meghan J Mooradian, et al.
Neuro-Oncology Advances
|
December 3, 2021
A review of neurotoxicities associated with immunotherapy and a framework for evaluation
Leeann B Burton, Mahsa Eskian, Amanda C Guidon, et al.
JAMA Network Open
|
October 14, 2020
Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
Tina R Watson, Xin Gao, Kerry L Reynolds, et al.
Current Cardiology Reports
|
July 1, 2021
Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors
David J Lee, Howard J Lee, Jocelyn R Farmer, et al.
Best Practice & Research. Clinical Haematology
|
September 7, 2025
Corrigendum to "Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)" [Best Pract Res Clin Haematol 38 2 2025]
Matthew J Hadfield, Ross D Merkin, Sherin J Rouhani, et al.
Page
of 16